Sary In patient tumour samples the activity in vitro of Taxol corresponded fairly well to the known clinical activity and Taxol showed low cross-resistance to standard cytotoxic drugs. However, tbe Taxol solvent Cremophor EL-ethanol was considerably active alone, wbereas paclitaxel formulated in ethanol was less active. Taxol thus seems to contain two components active against patient tumour cells in vitro.
Phase II studies have indicated activity of Taxol in several solid tumour types (Rowinsky et al., 1992) . The formulation of paclitaxel in 50% (v/v) Cremophor EL (CEL) and 50% ethanol (Taxol) potentially induces another type of antitumour activity. CEL has thus been found to reverse Pglycoprotein-mediated multidrug resistance (Schuurhuis et al., 1990; Fjallskog et al., 1994) and CEL may have a cytotoxic effect (Fjallskog et al., 1994) . Interestingly, concentrations of the solvent active in vitro may be reached in patients treated with Taxol (Webster et al., 1993) .
The present study was undertaken to investigate in vitro the activity of standard cytotoxic drugs in comparison with various formulations of paclitaxel and its solvent in tumour samples from patients and in a cell line, using the fluorometric microculture cytotoxicity assay (FMCA; Nygren et al., 1992 Nygren et al., , 1994a .
Materals and
Tunour sanples and cell preparatin The activity of Taxol and six standard cytotoxic drugs was tested in a total of 492 tumour samples obtained from patients with various tumour types as detailed in Table I . Because of the limited number of cells, not every sample was tested for every drug. The total numbers of samples included for each diagnosis and drug are indicated in Table I (Figure 1 ) of CEL (Sigma)/ethanol and paclitaxel (Sigma) dissolved in ethanol alone were used in control experiments to check for the effect of the solvents.
The six standard cytotoxic drugs tested are detailed in Table  I . The origin and solvents used for these drugs were as described previously Nygren et al., 1994a) . The cytotoxic drug concentrations used for activity evaluation, estabished from dose-response curve in haematological malignancies as described by , are indicated in Table I. FMCA procedure The principal steps of the assay have been described previously (Colton, 1974) .
Results
Dose-response relationships for Taxol in haematological and solid tumour samples indicated that the greatest response variation was observed at 5 jg ml-' with mean SI values of 32% and 56% respectively (Figure la and b) . This concentration was therefore used for testing samples with low cell yield.
The activity in vitro of Taxol and the standard drugs is shown in Table I Ewing's sarcoma (6), Wilms' tumour (6), neuroblastoma (7) and rhabdomyosarcoma (1). The assorted solid tumour group included adenocarcinomas of the parotid (3), thyroid (1), adrenal cortex (2), oesophagus (2), prostate (1), parathyroid (1) and medullary thyroid (2), melanoma (3), glioma (1), paraganglioma (1), carcinoid (5), squamous epithelial carcinoma (2) and hepatocellular carcinoma (1). Diagnosis abbreviations: ALL, acute lymphoblastic leukaemia; AML, acute myeloblastic leukaemia; NHL, non-Hodgkin's lymphoma; NSCLC, non-small-ell lung cancer; SCLC, small-cell lung cancer. Table I . Each correlation is based on 139-486 data points.
Discomso
The FMCA seems to detect disease-specific activity of standard drugs in haematological Nygren et al., , 1994b ) and solid tumours (Nygren et al., 1994a) . The present standard drug data add to the impron that the FMCA may be a valid assay. The FMCA may thus provide important information on the propertes of investigational drugs before those data can be extracted from cinical trials. Taxol has been found to be one of the most active drugs in patients with previously treated ovarian (Einzig et al., 1992; Rowinskly et al., 1992) and previously treated (Holmes et al., 1991; Nabholtz et al., 1993) or untreated (Seidman et al., 1992) breast carcinoma and with retained activity also in anthracycline-resistant breast carcinoma (Holmes et al., 1991; Seidman et al., 1993) . In untreated advanced NSCLC, the response rate seems to be low, slightly above 20% (Chang et al., 1992; Murphy et al., 1993) and no responses were observed in 18 patients with advanced kidney carcinoma (Einzig et al., 1991) .
The findings in vitro of a high activity of Taxol relative to standard drugs in carcinomas of the ovary and breast and the low activity in NSCLC and kidney carcinomas are thus reminiscent of the clinical data obtained so far and may indicate the vaLidity of the FMCA also for testng Taxol.
Much of the effect of Taxol in the patient tumour samples could be attributed to the solvent CEL, especially in the solid tumour samples. The biological activity of the pacitaxelethanol preparation was confirmed by a pronounced cytotoxic effect in the RPMI 8226 myeloma cell line, whereas in this system the solvents were relatively less cytotoxic. The latter pattern of activity of the various preparations has also been observed in breast cacer cell lines (Fjillskog et al., 1994) .
Could it be that the effects of Taxol and the solvent are not accurately measured in the FMCA? The quantitative effects of the paclitaxel and solvent preparations were confirmed in control experiments using the trypan blue exclusion test or a modification (Kristensen et al., 1992) of the well-established disc assay (Weisenthal et al., 1983) as end points (not shown). Furthermore, in control experiments, the redox indicator Alamar Blue (Alamar, Sacramento, CA, USA), which measures the metabolic activity of the cells, was used instead of FDA as viability indicator (Pag* et al., 1993) in the final step of the FMCA with essentially identical results (not shown).
It was recently found that a CEL concentration in plasma of >0.1% (v/v), which is close to the 0.042% at 5 tgml-' Taxol in vitro, is usually reached at the end of a 3 h Taxol infusion in patients (Webster et al., 1993) . It is not known if the tumour cells will really be exposed to these levels of CEL in vivo and if an anti-tumour effect could thus be obtained.
This could perhaps only be elucidated by actually treating patients with CEL alone.
CEL contains castor oiL which is a mixture of fatty acids (Budavari et al., 1989) which may be more toxic to tumour than to normal cells (Burton, 1991) and to multidrugresistant cells than to parental tumour cell lines (Weber et al., 1994) . The selectivity may be due to the apparent differences in the membrane compositions (Shinitzky and Inbar, 1974; Arsenault et al., 1988; Wseman, 1994) . We found a decrease in cell survival after only 3h of incubation in Taxol or CEL-ethanol (not shown) . This is reminiscent of the rapid cytotoxic effect of fatty acids (Burton, 1991) , indicating related mechnis of action. The possibility of a unique cytotoxic effect of CEL in Taxol would also explain the poor cross-resiance to the standard drugs.
The differences in activity of Taxol and its solvent between cell lines and the patient samples could be because cell ines under the present conditions proliferate, whereas the tumour cells from clinical samples in most cases do not. During its development Taxol was tested against proliferating cell lines in vitro or as xenografts in vivo prior to introduction of the drug in clnical studies (Rowinsky et al., 1992) . This might explain why a substantial effect of the solvent against patient tumour cells was never discovered. 
